| Patient | Joe Louis |
|---|---|
| Date of birth | 1971-05-13 |
| Identifiers | MRN HR-BX002-SYN; SSN (made up) 000-02-6639 |
| Document date | 2026-07-13 |
| Author | Desmond Achterberg-Cole, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for establishing primary care for persecutory thoughts and poor sleep two weeks after a collapse in the street: a nonjudgmental assessment of cocaine use, the differential of psychosis, a cognitive screen, safety, cardiovascular risk, harm reduction and money worries. [S]
White blood cells: 7.6 10*3/uL; Hemoglobin: 14.8 g/dL; MCV: 90 fL; Platelets: 236 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 1.16 mg/dL; eGFR (CKD-EPI 2021): 74 mL/min/1.73 m²; Glucose: 94 mg/dL; AST: 29 U/L; ALT: 33 U/L; Creatine kinase: 262 U/L; TSH: 1.9 mIU/L; Vitamin B12: 486 pg/mL; Hemoglobin A1c: 5.5%; DAST-10: 7; AUDIT-C: 3; PHQ-9: 8; GAD-7: 9; MoCA: 25. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-13 | Body height | 187 | cm | S |
| 2026-07-13 | Body weight | 101.2 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 28.9 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 154 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 102 | /min | S |
| 2026-07-13 | Respiratory rate | 16 | /min | S |
| 2026-07-13 | Body temperature | 36.9 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-13 | Leukocytes [#/volume] in Blood by Automated count | 7.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-13 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-07-13 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-07-13 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-13 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 10-40 U/L | Normal | S |
| 2026-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-56 U/L | Normal | S |
| 2026-07-13 | Creatine kinase [Enzymatic activity/volume] in Serum or Plasma | 262 | U/L | 39-308 U/L | Normal | S |
| 2026-07-13 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-07-13 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 486 | pg/mL | 200-900 pg/mL | Normal | S |
| 2026-07-13 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-07-13 | Total score [DAST-10] | 7 | {score} | S | ||
| 2026-07-13 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-07-13 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-07-13 | Total score [MoCA] | 25 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with fentanyl test strips and instruction for him and anyone he lives with | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-07-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persecutory thoughts and poor sleep for about two months: a fixed belief that people are following him and plan to harm him, three to four hours of sleep a night, partial insight; cause under evaluation | active | confirmed | R41.89 | S — Synthetic presenting problem anchored to his documented fears of a plot against his life; resolved into the diagnosis at the consultation. Not a claim about his real symptoms. |
| Cocaine use disorder, severe (seven of eleven DSM-5-TR criteria): intranasal cocaine most days for about a year, last use three days before intake | active | confirmed | F14.20 | S — Synthetic modern coding at intake; superseded at the consultation by the combined code once the psychotic disorder was diagnosed. Person-first language; not a claim about his real diagnosis. |
| Raised blood pressure at intake (154/98 mmHg) three days after cocaine use, without a diagnosis of hypertension; home readings planned | active | confirmed | R03.0 | S — Synthetic presenting finding; resolved into a diagnosis of hypertension at four weeks. |
| Financial insecurity: years of tax debt from his time as a well-paid athlete, now settled, left him with no savings; irregular income from paid appearances; worry about money keeps him awake | active | confirmed | Z59.86 | S — Synthetic social need anchored to his documented tax debt. |